©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2024; 16(9): 3875-3886
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3875
Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3875
Inflammation-related markers and prognosis of alpha-fetoprotein producing gastric cancer
Lu Zhang, Yan-Ping Chen, Min Ji, Le-Qian Ying, Chun-Chun Huang, Jing-Yi Zhou, Lin Liu, Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China
Author contributions: Liu L designed and directed the study; Zhang L wrote the manuscript draft; Liu L and Chen YP critically reviewed the manuscript; Zhang L, Ji M, Ying LQ, Huang CC and Zhou JY collected the original data; All authors reviewed the manuscript.
Institutional review board statement: This study design was approved by the ethics board of Zhongda Hospital of Southeast University, No. 2019ZDSYLL067-P01.
Informed consent statement: Informed consent of the patients could be waived because it was retrospective, and all information was anonymous.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available upon reasonable request at 101012478@seu.edu.cn.
Corresponding author: Lin Liu, MD, Chief Physician, Department of Oncology, Zhongda Hospital, Medical School of Southeast University, No. 87 Dingjiaqiao, Nanjing 210009, Jiangsu Province, China. 101012478@seu.edu.cn
Received: May 4, 2024
Revised: June 20, 2024
Accepted: July 15, 2024
Published online: September 15, 2024
Processing time: 128 Days and 4.6 Hours
Revised: June 20, 2024
Accepted: July 15, 2024
Published online: September 15, 2024
Processing time: 128 Days and 4.6 Hours
Core Tip
Core Tip: Compared with alpha-fetoprotein (AFP)- patients, the level of inflammation-related peripheral blood markers significantly increased in AFP+ patients, which was correlated with overall survival of AFP+ patients. AFP- producing gastric cancer (AFPGC) should be considered as a separate type and distinguished from AFP- gastric cancer because of the difference in tumor immune microenviroment. It might have different response rates in immunotherapy, which provided basis for selection of immunotherapy for AFPGC.